

IMEXPHARM CORPORATION

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: *03* /TTr-HĐQT-IMP

Dong Thap, March 25, 2026

PROPOSAL

Re.: Approval of the audited 2025 Financial Statements

Kindly Attn: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the Law on Enterprises;
- Pursuant to the Charter of Imexpharm Corporation (the “Company”);
- Based on the audited Financial statements prepared by KPMG Limited’s Branch in Ho Chi Minh City (Vietnam) dated March 20, 2026.

The Board of Directors (“BOD”) respectfully submits to the 2026 Annual General Meeting of Shareholders (“AGM”) for approval of the 2025 Financial statements of Imexpharm Corporation which has been audited by KPMG Limited’s Branch in Ho Chi Minh City (Vietnam) as follows:

The audited 2025 financial statements have been disclosed in accordance with regulations on the Company’s website, including:

1. Company’s profile;
2. Statement of the Board of Management;
3. Independent Auditor’s Report;
4. Balance sheet (Form No.B 01 – DN, Issued under Circular No. 200/2014/TT-BTC dated December 22, 2014 by the Ministry of Finance)
5. Income Statement (Form No. B02-DN);
6. Cash Flow Statement (Form No. B03-DN);
7. Notes to the Financial Statements (Form No. B09-DN).

In which:

Some basic indicators in the audited 2025 Financial statements:



No.	Key Targets	Unit	2025	2024
1	Total assets	VND	2,782,634,485,220	2,504,776,666,933
2	Revenue from sales of goods	VND	2,914,294,074,254	2,512,786,046,784
3	Net revenue	VND	2,441,085,482,086	2,205,119,938,413
4	Profit before tax	VND	446,247,738,093	404,192,934,555
5	Profit after tax	VND	349,138,023,396	320,862,393,082

Respectfully submitting to the AGM for consideration and approval.

ON BEHALF OF
 THE BOARD OF DIRECTORS
 CHAIRPERSON



SUNG MIN WOO

